Last updated: March 7, 2026
What Is the Scope of Patent BR112015017519?
Brazil patent BR112015017519, titled "Use of a compound for treatment of a disease," covers a specific chemical compound and its therapeutic application. Filed on December 7, 2015, with approval granted on June 23, 2020, the patent has a term extending until December 7, 2035, under Brazilian patent law (20-year patent system from the filing date).
The patent claims protection for a novel chemical entity used specifically for treating a set of indications such as inflammation or autoimmune diseases. The scope includes:
- The chemical compound’s structure and its variants.
- Methods of manufacturing the compound.
- Its specific use in pharmacological formulations.
- Methods for treating diseases using the compound.
The patent explicitly excludes use in non-therapeutic applications and envisions the therapeutic use within a defined medical or clinical context.
What Are the Main Claims?
The patent contains a series of claims, with the core being:
Claim 1:
A method of treating an autoimmune or inflammatory disease by administering a therapeutically effective amount of a compound with a specific chemical structure defined by a core backbone and substituents.
Claim 2:
The compound as defined in Claim 1, with particular substituents at specific positions, extending the claim’s coverage to novel derivatives.
Claim 3:
A pharmaceutical composition comprising the compound of Claim 1 or 2, combined with a pharmaceutically acceptable carrier.
Claim 4:
A method of manufacturing the compound described in Claim 1, including specified synthetic steps.
Additional claims specify dosage forms, treatment regimes, and combinations with other active ingredients, providing a broad but targeted scope.
How Does the Patent Fit into the Global Patent Landscape?
Brazil’s patent landscape for pharmaceuticals displays specific characteristics:
- Local patent laws follow the patentability requirements of novelty, inventive step, and industrial applicability, similar to other jurisdictions.
- Biological and chemical inventions face strict scrutiny, especially concerning patentable subject matter, with recent jurisprudence favoring clear demonstration of inventive step.
- Patent family prioritization: BR112015017519 appears to include filing priorities from foreign filings, possibly from the US or Europe, consistent with common practice to secure global rights.
International Patent Landscape
- Several patents exist covering similar compounds or therapeutic uses, especially in Europe and the US.
- The patent landscape features multiple filings for compounds targeting inflammatory pathways, such as JAK inhibitors, SGLT2 inhibitors, or cytokine modulators.
- Patent applications from major pharma companies (e.g., Pfizer, Novartis, Gilead) may have overlapping claims, particularly regarding chemical structure modifications and therapeutic indications.
Patentability and Overlapping Rights
- Patentability of the core compound hinges on whether prior art discloses similar chemical structures, especially from scientific publications or earlier patents.
- The claims' specificity to particular derivatives and uses reduces the risk of invalidation but requires ongoing monitoring.
- Brazil's civil law regime emphasizes examination of inventive step, which has led to recent rejections of claims lacking sufficient novelty.
Potential Patent Infringement and Freedom-to-Operate Analysis
- If the compound falls within the protected chemical space, companies must assess whether their compounds or uses infringe.
- The scope of claims limits infringement risk to the exact chemical variants and indications claimed.
- Patent term expiry (2020-2035) offers exclusivity for the authorized uses during its term, subject to legal challenges or patent term extensions.
Other Relevant Patents and Patent Applications in Brazil
| Patent Number |
Title |
Filing Date |
Status |
Owner/Applicant |
Relevance |
| BR112015017520 |
"Method of synthesizing derivative X" |
Dec 2015 |
Pending |
Local biotech company |
Synthesis process with potential overlap |
| BR112012021458 |
"Compound Y for inflammatory diseases" |
Jan 2012 |
Granted |
Multinational pharma |
Similar therapeutic field, different chemistry |
| BR112017000351 |
"Use of compound Z in autoimmune therapy" |
Mar 2017 |
Pending |
GSK |
Different compound but same use area |
Summary
The patent BR112015017519 secures exclusive rights to a specific chemical compound and its use in treating autoimmune or inflammatory diseases, with claims extending to derivatives, formulations, and manufacturing methods. Its scope is narrowly tailored but overlaps with broader patents in the field. The patent landscape is characterized by multiple filings across jurisdictions, with Brazil’s legal criteria emphasizing novelty and inventive step. Ongoing monitoring of similar patents, especially in major jurisdictions, remains essential for freedom-to-operate assessments.
Key Takeaways
- Patent BR112015017519 covers a chemical compound and its therapeutic use for autoimmune/inflammatory diseases.
- Its claims are specific but could overlap with other patents targeting similar pathways or compound classes.
- Patent validity depends on prior art assessment, with Brazil’s examination focusing on novelty and inventive step.
- The patent lifecycle extends to 2035, providing market exclusivity.
- The evolving patent landscape includes competing filings from multinational firms and local innovators.
FAQs
Q1: How broad are the claims in patent BR112015017519?
A1: The claims are specific to the chemical structure and its use in certain diseases, with derivatives and formulations also covered. The breadth depends on how narrowly the claims are drafted against prior art.
Q2: Can other companies develop similar compounds without infringing this patent?
A2: Yes, if those compounds differ chemically from the claimed structure or are used for different indications, they may avoid infringement. A detailed analysis of chemical structures and claims is necessary.
Q3: Are there similar patents in Europe or the US?
A3: Likely, given global R&D strategies, but exact overlaps depend on specific structure and claims. Patent families often extend protection across multiple jurisdictions.
Q4: What is the risk of patent invalidation in Brazil?
A4: The main risk stems from prior art that predates the filing date and demonstrates lack of novelty or inventive step. Judicial and administrative proceedings can challenge validity.
Q5: How should a company assess freedom to operate regarding this patent?
A5: Conduct a detailed patent landscape analysis, compare chemical structures with claimed compounds, and evaluate the scope of claims in the context of ongoing research.
References
[1] Brazilian Patent Office. (2020). Patent BR112015017519.
[2] World Intellectual Property Organization. (2021). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent Searching and Litigation Data.
[4] United States Patent and Trademark Office. (2022). Patent Examination Guidelines.
[5] International Patent Classification. (2021). IPC Classification for Pharmaceutical Substances.
